{
    "title": "Teva CEO says not too late to launch Humira biosimilar in 2024",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-12366127/Teva-CEO-says-not-late-launch-Humira-biosimilar-2024.html",
    "date": "2023-08-02",
    "keywords": [
        "francis",
        "drug",
        "year",
        "teva",
        "market",
        "price",
        "biosimilar",
        "humira",
        "opportunity",
        "number",
        "scheer",
        "jerusalem",
        "marketplace",
        "executive",
        "richard",
        "wednesday",
        "iceland",
        "production",
        "site",
        "inspection",
        "food",
        "administration",
        "approval",
        "half",
        "effort",
        "helm",
        "start",
        "room",
        "everybody",
        "advantage",
        "autoinjector",
        "therapy",
        "youve",
        "everything",
        "originator",
        "quality",
        "tevas",
        "benefit",
        "coverage",
        "pbms",
        "cigna",
        "unitedhealth",
        "amgen",
        "boehringer",
        "ingelheim",
        "novartis",
        "sandoz",
        "unit",
        "abbvie",
        "share",
        "erosion",
        "selling",
        "prescription",
        "pressure",
        "pampl",
        "theyve",
        "attrition",
        "discount",
        "biotech",
        "term",
        "pipeline",
        "version",
        "johnson",
        "psoriasis",
        "treatment",
        "stelara",
        "deal",
        "one",
        "strategy",
        "house",
        "reporting",
        "wingrove",
        "york",
        "editing",
        "humer",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}